Abstract
Segmental bone defects are a common obstacle in major orthopedic procedures, and the treatment of these defects remains a challenging clinical problem. Bone tissue engineering has been attracting much attention in recent years. We evaluated the ability of the specific combination of 3 μg rhVEGF165 with a novel porous β-tricalcium phosphate (b-TCP) scaffold coated with fibrin sealant (FS) to facilitate bone regeneration. Unilateral 15-mm long criticalsized defects were prepared in the radial diaphysis of rabbits and treated with rhVEGF165/FS/scaffold or FS/scaffold. Healing of the defects was assessed at 4, 8, and 12 weeks, radiologically, histologically, and biomechanically. The results of the study demonstrated that the critical-sized defects in the midshaft of the rabbit radius, treated with rhVEGF165 incorporated in porous β-TCP scaffold by FS, can be completely bridged by cortical bone in 12 weeks. The bone marrow space was also reformed histologically and radiologically at 12 weeks postsurgery in the rhVEGF165-treated group. Furthermore, biomechanical examination demonstrated that the segmental bone defects were not only radiologically and histologically repaired but were also mechanically repaired. Interestingly, none of the defects was completely repaired at 12 weeks following treatment with FS/ scaffold without rhVEGF165. A solution-driven process is likely the predominant mechanism of accelerating biodegradation of the β-TCP scaffold in the presence of rhVEGF 165; furthermore, cell-mediated phagocytosis also contributes to biodegradation of the biomaterials.
| Original language | English |
|---|---|
| Pages (from-to) | 626-640 |
| Number of pages | 15 |
| Journal | Journal of Biomedical Materials Research - Part A |
| Volume | 92 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2010 |
Fingerprint
Keywords
- Adsorption
- Biomaterial
- Osteogenesis
- Tissue engineering
- Vascular endothelial growth factor
ASJC Scopus subject areas
- Biomedical Engineering
- Biomaterials
- Ceramics and Composites
- Metals and Alloys
Cite this
RhVEGF165 delivered in a porous β-tricalcium phosphate scaffold accelerates bridging of critical-sized defects in rabbit radii. / Yang, Pei; Wang, Chunsheng; Shi, Zhibin; Huang, Xin; Dang, Xiaoqian; Li, Xudong; Lin, Shien-Fong; Wang, Kunzheng.
In: Journal of Biomedical Materials Research - Part A, Vol. 92, No. 2, 02.2010, p. 626-640.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - RhVEGF165 delivered in a porous β-tricalcium phosphate scaffold accelerates bridging of critical-sized defects in rabbit radii
AU - Yang, Pei
AU - Wang, Chunsheng
AU - Shi, Zhibin
AU - Huang, Xin
AU - Dang, Xiaoqian
AU - Li, Xudong
AU - Lin, Shien-Fong
AU - Wang, Kunzheng
PY - 2010/2
Y1 - 2010/2
N2 - Segmental bone defects are a common obstacle in major orthopedic procedures, and the treatment of these defects remains a challenging clinical problem. Bone tissue engineering has been attracting much attention in recent years. We evaluated the ability of the specific combination of 3 μg rhVEGF165 with a novel porous β-tricalcium phosphate (b-TCP) scaffold coated with fibrin sealant (FS) to facilitate bone regeneration. Unilateral 15-mm long criticalsized defects were prepared in the radial diaphysis of rabbits and treated with rhVEGF165/FS/scaffold or FS/scaffold. Healing of the defects was assessed at 4, 8, and 12 weeks, radiologically, histologically, and biomechanically. The results of the study demonstrated that the critical-sized defects in the midshaft of the rabbit radius, treated with rhVEGF165 incorporated in porous β-TCP scaffold by FS, can be completely bridged by cortical bone in 12 weeks. The bone marrow space was also reformed histologically and radiologically at 12 weeks postsurgery in the rhVEGF165-treated group. Furthermore, biomechanical examination demonstrated that the segmental bone defects were not only radiologically and histologically repaired but were also mechanically repaired. Interestingly, none of the defects was completely repaired at 12 weeks following treatment with FS/ scaffold without rhVEGF165. A solution-driven process is likely the predominant mechanism of accelerating biodegradation of the β-TCP scaffold in the presence of rhVEGF 165; furthermore, cell-mediated phagocytosis also contributes to biodegradation of the biomaterials.
AB - Segmental bone defects are a common obstacle in major orthopedic procedures, and the treatment of these defects remains a challenging clinical problem. Bone tissue engineering has been attracting much attention in recent years. We evaluated the ability of the specific combination of 3 μg rhVEGF165 with a novel porous β-tricalcium phosphate (b-TCP) scaffold coated with fibrin sealant (FS) to facilitate bone regeneration. Unilateral 15-mm long criticalsized defects were prepared in the radial diaphysis of rabbits and treated with rhVEGF165/FS/scaffold or FS/scaffold. Healing of the defects was assessed at 4, 8, and 12 weeks, radiologically, histologically, and biomechanically. The results of the study demonstrated that the critical-sized defects in the midshaft of the rabbit radius, treated with rhVEGF165 incorporated in porous β-TCP scaffold by FS, can be completely bridged by cortical bone in 12 weeks. The bone marrow space was also reformed histologically and radiologically at 12 weeks postsurgery in the rhVEGF165-treated group. Furthermore, biomechanical examination demonstrated that the segmental bone defects were not only radiologically and histologically repaired but were also mechanically repaired. Interestingly, none of the defects was completely repaired at 12 weeks following treatment with FS/ scaffold without rhVEGF165. A solution-driven process is likely the predominant mechanism of accelerating biodegradation of the β-TCP scaffold in the presence of rhVEGF 165; furthermore, cell-mediated phagocytosis also contributes to biodegradation of the biomaterials.
KW - Adsorption
KW - Biomaterial
KW - Osteogenesis
KW - Tissue engineering
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=75149134227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75149134227&partnerID=8YFLogxK
U2 - 10.1002/jbm.a.32403
DO - 10.1002/jbm.a.32403
M3 - Article
VL - 92
SP - 626
EP - 640
JO - Journal of Biomedical Materials Research - Part A
JF - Journal of Biomedical Materials Research - Part A
SN - 1549-3296
IS - 2
ER -